Phase III/Seroquel SR Bipolar Depression Monotherapy - US - Full Text View

Sponsor:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00422214

Purpose

The purpose of this study is to determine the safety and efficacy of sustained-release quetiapine fumarate (Seroquel®) in the treatment of patients with Acute Bipolar Depression for 8 weeks.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Condition	Intervention	Phase
Affective Psychosis, Bipolar Depression, Bipolar Manic-Depressive Psychosis Psychoses, Manic-Depressive	Drug: Quetiapine fumarate (Seroquel) SR	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel SR®) Sustained-Release as Monotherapy in Adult Patients With Acute Bipolar Depression

Resource links provided by NLM:

MedlinePlus related topics: Bipolar Disorder Depression Psychotic Disorders

Drug Information available for: Quetiapine Quetiapine fumarate

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Change from baseline in depression symptoms by final visit as measured by the MADRS total score

Secondary Outcome Measures:

Change from baseline to final visit on the MADRS total score MADRS item scores, CGI-BP-S, CGI-BP-C

Estimated Enrollment:	400
Study Start Date:	December 2006
Study Completion Date:	June 2007

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Provision of written informed consent
Documented diagnosis of Bipolar 1 disorder or Bipolar 11 disorder
Outpatient status at enrollment

Exclusion Criteria:

Patients with >8 mood episodes during the past 12 years
Use of prohibited medications
Substance or alcohol abuse or dependence
Current suicide risk or suicide attempt within last 6 months.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00422214

Hide Study Locations

Locations

United States, Alabama
Research Site
BIRMINGHAM, Alabama, United States
United States, Arizona
Research Site
PHOENIX, Arizona, United States
Research Site
SCOTTSDALE, Arizona, United States
United States, Arkansas
Research Site
LITTLE ROCK, Arkansas, United States
United States, California
Research Site
CERRITOS, California, United States
Research Site
LA MESA, California, United States
Research Site
WILDOMAR, California, United States
Research Site
NEWPORT BEACH, California, United States
Research Site
NORTHRIDGE, California, United States
Research Site
OCEANSIDE, California, United States
Research Site
PICO RIVERA, California, United States
Research Site
SAN DIEGO, California, United States
Research Site
LOS ANGELES, California, United States
United States, District of Columbia
Research Site
WASHINGTON, District of Columbia, United States
United States, Florida
Research Site
BRADENTON, Florida, United States
Research Site
FORT LAUDERDALE, Florida, United States
Research Site
JACKSONVILLE, Florida, United States
Research Site
NORTH MIAMI, Florida, United States
Research Site
MAITLAND, Florida, United States
Research Site
LEESBURG, Florida, United States
Research Site
ORLANDO, Florida, United States
Research Site
TAMPA, Florida, United States
Research Site
WEST PALM BEACH, Florida, United States
United States, Georgia
Research Site
SMYRNA, Georgia, United States
United States, Hawaii
Research Site
HONOLULU, Hawaii, United States
United States, Illinois
Research Site
JOLIET, Illinois, United States
United States, Indiana
Research Site
GREENWOOD, Indiana, United States
Research Site
INDIANAPOLIS, Indiana, United States
United States, Kansas
Research Site
WICHITA, Kansas, United States
United States, Louisiana
Research Site
SHREVEPORT, Louisiana, United States
United States, Maryland
Research Site
ROCKVILLE, Maryland, United States
United States, Michigan
Research Site
FARMINGTON HILLS, Michigan, United States
United States, Missouri
Research Site
ST. LOUIS, Missouri, United States
United States, New Jersey
Research Site
CHERRY HILL, New Jersey, United States
Research Site
CLEMENTON, New Jersey, United States
United States, New York
Research Site
BROOKLYN, New York, United States
Research Site
NEW YORK, New York, United States
Research Site
STATEN ISLAND, New York, United States
United States, Ohio
Research Site
DAYTON, Ohio, United States
Research Site
CINCINNATI, Ohio, United States
Research Site
BEACHWOOD, Ohio, United States
United States, Oklahoma
Research Site
OKLAHOMA CITY, Oklahoma, United States
United States, Oregon
Research Site
PORTLAND, Oregon, United States
Research Site
SALEM, Oregon, United States
United States, Pennsylvania
Research Site
PHILADELPHIA, Pennsylvania, United States
United States, South Carolina
Research Site
CHARLESTON, South Carolina, United States
United States, Tennessee
Research Site
MEMPHIS, Tennessee, United States
United States, Texas
Research Site
DALLAS, Texas, United States
Research Site
HOUSTON, Texas, United States
United States, Virginia
Research Site
CHARLOTTESVILLE, Virginia, United States
Research Site
VIRGINIA BEACH, Virginia, United States
United States, Washington
Research Site
BELLEVUE, Washington, United States
Research Site
SEATTLE, Washington, United States
Research Site
SOUTH KIRKLAND, Washington, United States

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:	Catherine Datto, MD	AstraZeneca
Study Director:	Larisa Acevedo, Ph.D	AstraZeneca

More Information

No publications provided

Study ID Numbers:	D144CC00002
Study First Received:	January 12, 2007
Last Updated:	March 24, 2009
ClinicalTrials.gov Identifier:	NCT00422214 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by AstraZeneca:

Bipolar Disorder
Bipolar Depression,
Manic Depression

Seroquel
Seroquel SR
quetiapine fumarate

Additional relevant MeSH terms:

Depression
Tranquilizing Agents
Bipolar Disorder
Physiological Effects of Drugs
Psychotropic Drugs
Central Nervous System Depressants
Depressive Disorder, Major
Depressive Disorder
Antipsychotic Agents
Pharmacologic Actions

Behavioral Symptoms
Affective Disorders, Psychotic
Quetiapine
Mental Disorders
Therapeutic Uses
Mood Disorders
Psychotic Disorders
Central Nervous System Agents
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on November 25, 2009